{"id":"fdc","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without access to detailed clinical trial data or published mechanisms, the precise molecular target and pharmacological action cannot be reliably determined. The drug is in Phase 3 development under a cardiovascular research organization, suggesting a focus on heart disease or related conditions, but the exact mechanism remains proprietary or undisclosed.","oneSentence":"FDC is a cardiovascular investigational drug developed by a Spanish research foundation, but its specific mechanism of action is not publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:20.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07210723","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Kardigan, Inc.","startDate":"2026-02-13","conditions":"Symptomatic Genetic Dilated Cardiomyopathy","enrollment":332},{"nctId":"NCT06594991","phase":"PHASE2","title":"A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-10","conditions":"Advanced Melanoma","enrollment":88},{"nctId":"NCT04785820","phase":"PHASE2","title":"A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Advanced or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":190},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT05287113","phase":"PHASE2","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences International Sàrl","startDate":"2022-11-14","conditions":"Head and Neck Cancer","enrollment":176},{"nctId":"NCT06325683","phase":"PHASE2","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-11-08","conditions":"Progressive Glioblastoma, Recurrent Glioblastoma","enrollment":184},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT07365839","phase":"PHASE1","title":"Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2026-07-01","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT07492680","phase":"PHASE2","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-07-17","conditions":"Solid Tumors","enrollment":260},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT02881320","phase":"PHASE2, PHASE3","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-09-21","conditions":"HIV-1 Infection","enrollment":177},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT03044613","phase":"PHASE1","title":"Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-07-11","conditions":"Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer","enrollment":32},{"nctId":"NCT06769698","phase":"PHASE2","title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":120},{"nctId":"NCT06036836","phase":"PHASE2","title":"Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-09-29","conditions":"Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer","enrollment":163},{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":"Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia","enrollment":103},{"nctId":"NCT07354516","phase":"PHASE2, PHASE3","title":"Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2026-03-18","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":36},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT04140500","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-11-11","conditions":"Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer","enrollment":170},{"nctId":"NCT07300280","phase":"PHASE1","title":"A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-29","conditions":"Healthy","enrollment":60},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT04256317","phase":"PHASE2, PHASE3","title":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2020-05-21","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm","enrollment":316},{"nctId":"NCT06205836","phase":"PHASE2","title":"Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-06-13","conditions":"Colorectal Cancer","enrollment":44},{"nctId":"NCT03607890","phase":"PHASE2","title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-16","conditions":"Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors","enrollment":38},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT05179876","phase":"PHASE3","title":"A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option","status":"RECRUITING","sponsor":"Actelion","startDate":"2022-05-04","conditions":"Hypertension, Pulmonary","enrollment":280},{"nctId":"NCT06708949","phase":"PHASE2","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-03-20","conditions":"Renal Cell Carcinoma, Clear Cell","enrollment":15},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT06193408","phase":"PHASE2","title":"Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera","status":"COMPLETED","sponsor":"Hunazine Biotech S.L.","startDate":"2024-02-11","conditions":"Cholera","enrollment":150},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT07237594","phase":"PHASE1","title":"IL-17 Blockade to Decrease irAEs (REPLAY)","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-05-01","conditions":"Metastatic Melanoma","enrollment":4},{"nctId":"NCT07219602","phase":"PHASE3","title":"A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome","status":"RECRUITING","sponsor":"NewAmsterdam Pharma","startDate":"2025-12-11","conditions":"Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)","enrollment":300},{"nctId":"NCT07349394","phase":"PHASE1","title":"Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2026-01-12","conditions":"Cystic Fibrosis","enrollment":18},{"nctId":"NCT07046975","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07459543","phase":"PHASE4","title":"A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-11-15","conditions":"Untreated Melanoma, Unresectable Melanoma, Metastatic Melanoma","enrollment":30},{"nctId":"NCT07015671","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-07-01","conditions":"Bioequivalence Study in Healthy Subjects, PK/PD","enrollment":24},{"nctId":"NCT07043634","phase":"PHASE3","title":"A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07452913","phase":"PHASE4","title":"Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT06139796","phase":"PHASE1, PHASE2","title":"Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV","status":"WITHDRAWN","sponsor":"PENTA Foundation","startDate":"2025-02-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT03026140","phase":"PHASE2","title":"Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-03-29","conditions":"Colon Carcinoma","enrollment":353},{"nctId":"NCT07179315","phase":"PHASE2","title":"A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-12-01","conditions":"Head and Neck Cancer","enrollment":68},{"nctId":"NCT04895722","phase":"PHASE2","title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-25","conditions":"Colorectal Cancer","enrollment":302},{"nctId":"NCT07404137","phase":"PHASE1","title":"A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-16","conditions":"Healthy Participants","enrollment":26},{"nctId":"NCT07442630","phase":"PHASE4","title":"Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides","status":"ACTIVE_NOT_RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2023-08-21","conditions":"Hypercholesterolemia","enrollment":88},{"nctId":"NCT07223541","phase":"PHASE2","title":"Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-01-15","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":72},{"nctId":"NCT06101342","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":181},{"nctId":"NCT07268625","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-12-09","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT04375800","phase":"PHASE2","title":"Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-03","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":84},{"nctId":"NCT06918132","phase":"PHASE2","title":"Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-29","conditions":"Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":60},{"nctId":"NCT05403450","phase":"PHASE1","title":"A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-02-22","conditions":"Relapsed/Refractory Peripheral T-cell Lymphoma","enrollment":33},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT03252938","phase":"PHASE1","title":"Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2017-08-15","conditions":"Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma","enrollment":83},{"nctId":"NCT06246916","phase":"PHASE3","title":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-09","conditions":"Melanoma","enrollment":560},{"nctId":"NCT04223778","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":672},{"nctId":"NCT06963905","phase":"PHASE1, PHASE2","title":"Saci Nivo Rela for TNBC","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-29","conditions":"Metastatic Triple-negative Breast Cancer","enrollment":60},{"nctId":"NCT05912244","phase":"PHASE2","title":"A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-06-09","conditions":"Melanoma","enrollment":43},{"nctId":"NCT06151236","phase":"PHASE2","title":"Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2024-03-11","conditions":"Merkel Cell Carcinoma","enrollment":20},{"nctId":"NCT07234058","phase":"PHASE2","title":"Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma","status":"NOT_YET_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-02","conditions":"Pleural Mesotheliomas","enrollment":126},{"nctId":"NCT06190951","phase":"PHASE2","title":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-18","conditions":"Melanoma","enrollment":151},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT05661578","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-05-04","conditions":"PD-L1-selected Solid Tumors","enrollment":64},{"nctId":"NCT05418972","phase":"PHASE2","title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2023-08-14","conditions":"Stage II Melanoma","enrollment":20},{"nctId":"NCT07224022","phase":"PHASE2","title":"Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"John Strickler, M.D.","startDate":"2026-02","conditions":"Colon Cancer","enrollment":24},{"nctId":"NCT05052996","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-05","conditions":"HIV-1 Infection","enrollment":142},{"nctId":"NCT07235189","phase":"PHASE1","title":"A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-28","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT05645692","phase":"PHASE2","title":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-04-13","conditions":"Urothelial Cancer","enrollment":204},{"nctId":"NCT07376512","phase":"","title":"Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis","status":"NOT_YET_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2026-03-01","conditions":"Non-Small Cell Lung Cancer, Melanoma (Skin Cancer)","enrollment":378},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT04989946","phase":"PHASE1, PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT07016490","phase":"PHASE1","title":"A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-06-12","conditions":"Advanced Malignant Tumors","enrollment":15},{"nctId":"NCT05800015","phase":"PHASE2, PHASE3","title":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-08-08","conditions":"Non-small Cell Lung Cancer","enrollment":950},{"nctId":"NCT05785767","phase":"PHASE2, PHASE3","title":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-06-30","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":850},{"nctId":"NCT05331183","phase":"PHASE3","title":"Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-11-23","conditions":"Cystic Fibrosis","enrollment":297},{"nctId":"NCT07037277","phase":"PHASE3","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-06-02","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection","enrollment":880},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT06056895","phase":"PHASE2","title":"Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2023-11-08","conditions":"Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma","enrollment":12},{"nctId":"NCT05704647","phase":"PHASE2","title":"Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-02-23","conditions":"Melanoma (Skin)","enrollment":30},{"nctId":"NCT06532656","phase":"PHASE2, PHASE3","title":"Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-11-20","conditions":"HIV-1-infection","enrollment":75},{"nctId":"NCT07333742","phase":"PHASE1","title":"A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal","status":"COMPLETED","sponsor":"LG Chem","startDate":"2025-09-29","conditions":"Fed Conditions, Healthy Volunteer","enrollment":50},{"nctId":"NCT01854775","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05-06","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":129},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT04326257","phase":"PHASE2","title":"Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy","status":"COMPLETED","sponsor":"Dan Zandberg","startDate":"2020-05-14","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":20},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT01968109","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-11-05","conditions":"Neoplasms by Site","enrollment":1482},{"nctId":"NCT04578106","phase":"PHASE2","title":"Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy","status":"TERMINATED","sponsor":"Fundacio Clinic Barcelona","startDate":"2020-09-23","conditions":"HER2-positive Breast Cancer, Stage I Breast Cancer","enrollment":5},{"nctId":"NCT06544733","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-20","conditions":"HIV-1-Infection","enrollment":675},{"nctId":"NCT05428007","phase":"PHASE2","title":"Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-02-02","conditions":"Melanoma, Unresectable Melanoma","enrollment":105},{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT06397144","phase":"PHASE1","title":"A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2025-08-15","conditions":"Biological Availability, Healthy Participants","enrollment":""},{"nctId":"NCT07206472","phase":"","title":"A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-01-30","conditions":"Primary Hypercholesterolaemia, Mixed Dyslipidemia","enrollment":2560},{"nctId":"NCT04776252","phase":"PHASE3","title":"Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-15","conditions":"HIV-1 Infection","enrollment":2000},{"nctId":"NCT05352672","phase":"PHASE3","title":"Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-07-14","conditions":"Melanoma","enrollment":1546},{"nctId":"NCT03610711","phase":"PHASE1, PHASE2","title":"REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-03-06","conditions":"Gastroesophageal Cancer, Immune Checkpoint Inhibition","enrollment":21},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT03904693","phase":"PHASE3","title":"Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2019-07-29","conditions":"Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","enrollment":187},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3384,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FDC","genericName":"FDC","companyName":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","companyId":"fundaci-n-centro-nacional-de-investigaciones-cardiovasculares-carlos-iii","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}